688520 神州细胞
交易中 11-04 14:38:54
资讯
新帖
简况
股市必读：神州细胞新发布《神州细胞关于控股股东、实际控制人自愿承诺不减持公司股份的公告》
证券之星 · 11-03 02:38
股市必读：神州细胞新发布《神州细胞关于控股股东、实际控制人自愿承诺不减持公司股份的公告》
股市必读：神州细胞三季报 - 第三季度单季净利润同比下降28.20%
证券之星 · 11-02 08:58
股市必读：神州细胞三季报 - 第三季度单季净利润同比下降28.20%
神州细胞：控股股东、实控人承诺12个月内不减持公司股份
同花顺 · 11-01 15:36
神州细胞：控股股东、实控人承诺12个月内不减持公司股份
神州细胞(688520)9月30日股东户数1.34万户，较上期增加16.93%
证券之星 · 10-31
神州细胞(688520)9月30日股东户数1.34万户，较上期增加16.93%
股市必读：神州细胞新发布《神州细胞股东减持股份计划公告》
证券之星 · 10-15
股市必读：神州细胞新发布《神州细胞股东减持股份计划公告》
神州细胞最新公告：股东拟合计减持不超0.03%股份
证券之星 · 10-13
神州细胞最新公告：股东拟合计减持不超0.03%股份
神州细胞（688520）披露控股子公司SCT810获临床试验批准通知书，10月13日股价下跌3.47%
证券之星 · 10-13
神州细胞（688520）披露控股子公司SCT810获临床试验批准通知书，10月13日股价下跌3.47%
神州细胞最新公告：子公司产品SCT810获得药物临床试验批准
证券之星 · 10-12
神州细胞最新公告：子公司产品SCT810获得药物临床试验批准
神州细胞（688520）10月9日主力资金净买入1338.72万元
证券之星 · 10-10
神州细胞（688520）10月9日主力资金净买入1338.72万元
神州细胞集团公司（688520）9月24日主力资金净卖出1231.62万元
证券之星 · 09-25
神州细胞集团公司（688520）9月24日主力资金净卖出1231.62万元
神州细胞（688520.SH）A+H最新进展
中金财经 · 09-20
神州细胞（688520.SH）A+H最新进展
每周股票复盘：神州细胞集团公司（688520）股东拟合计减持不超0.94%股份
证券之星 · 09-20
每周股票复盘：神州细胞集团公司（688520）股东拟合计减持不超0.94%股份
神州细胞：9月16日召开业绩说明会，投资者参与
证券之星 · 09-17
神州细胞：9月16日召开业绩说明会，投资者参与
神州细胞(688520.SH)股东拟合计减持不超0.94%股份
智通财经 · 09-13
神州细胞(688520.SH)股东拟合计减持不超0.94%股份
神州细胞（688520）披露2026年半年度报告，8月31日股价下跌3.73%
证券之星 · 08-31
神州细胞（688520）披露2026年半年度报告，8月31日股价下跌3.73%
神州细胞（688520）2026年中报简析：净利润同比下降982.86%，三费占比上升明显
证券之星 · 08-30
神州细胞（688520）2026年中报简析：净利润同比下降982.86%，三费占比上升明显
图解神州细胞中报：第二季度单季净利润同比下降94.80%
证券之星 · 08-29
图解神州细胞中报：第二季度单季净利润同比下降94.80%
每周股票复盘：神州细胞（688520）SCTA02A获乙肝临床试验批准
证券之星 · 08-23
每周股票复盘：神州细胞（688520）SCTA02A获乙肝临床试验批准
神州细胞最新公告：控股子公司产品SCTA02A获药物临床试验批准
证券之星 · 08-19
神州细胞最新公告：控股子公司产品SCTA02A获药物临床试验批准
神州细胞冲刺港股IPO：集采重创“现金奶牛”，盈亏反复造血乏力，烧钱不止负债攀升
证券之星 · 06-24
神州细胞冲刺港股IPO：集采重创“现金奶牛”，盈亏反复造血乏力，烧钱不止负债攀升
加载更多
公司概况
公司名称：
北京神州细胞生物技术集团股份公司
所属行业：
医药制造业
上市日期：
2020-06-22
主营业务：
北京神州细胞生物技术集团股份公司的主营业务是治疗性抗体、重组蛋白及疫苗的研发、生产与商业化。公司的主要产品是重组蛋白药物、抗体药物。
发行价格：
25.64
{"stockData":{"symbol":"688520","market":"SH","secType":"STK","nameCN":"神州细胞","latestPrice":32.39,"timestamp":1793774334000,"preClose":30.23,"halted":0,"volume":3265193,"delay":0,"changeRate":0.0715,"floatShares":445000000,"shares":470000000,"eps":-2.0368,"marketStatus":"交易中","change":2.16,"latestTime":"11-04 14:38:54","open":30.23,"high":32.48,"low":30.07,"amount":102000000,"amplitude":0.0797,"askPrice":32.39,"askSize":39,"bidPrice":32.31,"bidSize":23,"shortable":0,"etf":0,"ttmEps":-2.0368,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1793775600000},"marketStatusCode":2,"adr":0,"adjPreClose":30.23,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793755800000,1793763000000],[1793768400000,1793775600000]],"highLimit":33.25,"lowLimit":27.21,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":470335714,"isCdr":false,"pbRate":-33.16,"roa":"--","roe":"--","epsLYR":-1.32,"committee":-0.027397,"marketValue":15234000000,"turnoverRate":0.0073,"status":0,"floatMarketCap":14424000000},"requestUrl":"/m/hq/s/688520/","defaultTab":"news","newsList":[{"id":"2680762205","title":"股市必读：神州细胞新发布《神州细胞关于控股股东、实际控制人自愿承诺不减持公司股份的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2680762205","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680762205?lang=zh_cn&edition=full","pubTime":"2026-11-03 02:38","pubTimestamp":1793644706,"startTime":"0","endTime":"0","summary":"截至2026年11月2日收盘，神州细胞报收于30.37元，下跌2.28%，换手率0.88%，成交量3.94万手，成交额1.17亿元。公司公告汇总：控股股东拉萨爱力克及实际控制人谢良志博士自愿承诺自2026年11月2日起未来12个月内不以任何形式减持所持公司股份。交易信息汇总资金流向11月2日主力资金净流出237.31万元，占总成交额2.03%；游资资金净流入283.7万元，占总成交额2.42%；散户资金净流出46.39万元，占总成交额0.4%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300004529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680874786","title":"股市必读：神州细胞三季报 - 第三季度单季净利润同比下降28.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680874786","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680874786?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:58","pubTimestamp":1793581092,"startTime":"0","endTime":"0","summary":"截至2026年10月30日收盘，神州细胞报收于31.08元，下跌1.74%，换手率0.52%，成交量2.32万手，成交额7305.86万元。公司公告汇总神州细胞2026年第三季度报告2026年第三季度营业收入2.32亿元，同比下降31.61%；前三季度累计营业收入8.92亿元，同比下降32.02%。截至公告日，拉萨爱力克持有公司62.98%股份，谢良志持有3.63%股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200002994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680205918","title":"神州细胞：控股股东、实控人承诺12个月内不减持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2680205918","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680205918?lang=zh_cn&edition=full","pubTime":"2026-11-01 15:36","pubTimestamp":1793518560,"startTime":"0","endTime":"0","summary":"人民财讯11月1日电，神州细胞(688520)11月1日公告，公司控股股东和实际控制人自愿承诺，自2026年11月2日起未来12个月内(即2026年11月2日至2027年11月1日)，不以任何形式减持其直接持有的公 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261101/c681326981.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261101/c681326981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679427870","title":"神州细胞(688520)9月30日股东户数1.34万户，较上期增加16.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679427870","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679427870?lang=zh_cn&edition=full","pubTime":"2026-10-31 17:18","pubTimestamp":1793438322,"startTime":"0","endTime":"0","summary":"证券之星消息，近日神州细胞披露，截至2026年9月30日公司股东户数为1.34万户，较6月30日增加1941.0户，增幅为16.93%。在生物制品行业个股中，神州细胞股东户数低于行业平均水平，截至9月30日，生物制品行业平均股东户数为3.67万户。从股价来看，2026年6月30日至2026年9月30日，神州细胞区间涨幅为8.3%，在此期间股东户数增加1941.0户，增幅为16.93%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100033403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675215613","title":"股市必读：神州细胞新发布《神州细胞股东减持股份计划公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675215613","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675215613?lang=zh_cn&edition=full","pubTime":"2026-10-15 02:14","pubTimestamp":1792001650,"startTime":"0","endTime":"0","summary":"公司公告汇总神州细胞股东减持股份计划公告北京神州细胞生物技术集团股份公司股东神州安隆、神州安干因个人资金需求，计划通过集中竞价交易方式减持公司股份，合计不超过133,300股，占公司总股本不超过0.03%。上述股东为一致行动人，合计持股7.37%。公司控股股东、实际控制人承诺不参与本次减持。本次减持符合相关法律法规规定，不会导致公司控制权变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500001794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675354715","title":"神州细胞最新公告：股东拟合计减持不超0.03%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2675354715","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675354715?lang=zh_cn&edition=full","pubTime":"2026-10-13 20:39","pubTimestamp":1791895183,"startTime":"0","endTime":"0","summary":"神州细胞(688520.SH)公告称，公司股东暨员工持股平台神州安隆、神州安干因个人资金需求，计划通过集中竞价交易方式减持合计不超过133,300股，占公司总股本不超过0.03%。减持期间为公告披露之日起15个交易日后的3个月内。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300036890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675303143","title":"神州细胞（688520）披露控股子公司SCT810获临床试验批准通知书，10月13日股价下跌3.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675303143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675303143?lang=zh_cn&edition=full","pubTime":"2026-10-13 17:34","pubTimestamp":1791884070,"startTime":"0","endTime":"0","summary":"截至2026年10月13日收盘，神州细胞报收于33.66元，较前一交易日下跌3.47%，最新总市值为158.32亿元。近日，神州细胞发布自愿披露公告，称其控股子公司神州细胞工程有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意其自主研发的SCT810注射液开展用于伴或不伴抑制物的中重型血友病A或血友病B患者的临床试验。药品研发存在高风险，临床试验结果及上市进度存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300029524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674487037","title":"神州细胞最新公告：子公司产品SCT810获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2674487037","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674487037?lang=zh_cn&edition=full","pubTime":"2026-10-12 20:31","pubTimestamp":1791808261,"startTime":"0","endTime":"0","summary":"神州细胞(688520.SH)公告称，近日，公司控股子公司神州细胞工程有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司自主研发的产品SCT810注射液开展伴或不伴抑制物的中重型血友病A（HA）或血友病B（HB）患者的临床试验。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200032036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674867023","title":"神州细胞（688520）10月9日主力资金净买入1338.72万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674867023","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674867023?lang=zh_cn&edition=full","pubTime":"2026-10-10 08:16","pubTimestamp":1791591371,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月9日收盘，神州细胞报收于36.22元，上涨4.38%，换手率0.87%，成交量3.89万手，成交额1.38亿元。近5日资金流向一览见下表：神州细胞融资融券信息显示，融资方面，当日融资买入998.95万元，融资偿还1309.74万元，融资净偿还310.78万元。神州细胞主营业务：专注于恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101000003832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670194164","title":"神州细胞集团公司（688520）9月24日主力资金净卖出1231.62万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670194164","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670194164?lang=zh_cn&edition=full","pubTime":"2026-09-25 08:31","pubTimestamp":1790296314,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，神州细胞集团公司报收于35.75元，下跌3.95%，换手率0.86%，成交量3.82万手，成交额1.39亿元。近5日资金流向一览见下表：神州细胞集团公司融资融券信息显示，融资方面，当日融资买入881.05万元，融资偿还722.07万元，融资净买入158.98万元。神州细胞集团公司主营业务：专注于恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092500005273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668690758","title":"神州细胞（688520.SH）A+H最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2668690758","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668690758?lang=zh_cn&edition=full","pubTime":"2026-09-20 10:30","pubTimestamp":1789871401,"startTime":"0","endTime":"0","summary":"二、请逐项列示本次发行募集资金用于境内外投资项目的具体金额及比例，并说明相关审批、核准或备案程序履行情况，如在履行相关程序过程中请出具募集资金全部调回境内的承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260920/32375467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668390672","title":"每周股票复盘：神州细胞集团公司（688520）股东拟合计减持不超0.94%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2668390672","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668390672?lang=zh_cn&edition=full","pubTime":"2026-09-20 01:35","pubTimestamp":1789839311,"startTime":"0","endTime":"0","summary":"截至2026年9月18日收盘，神州细胞集团公司报收于33.71元，较上周的32.41元上涨4.01%。本周，神州细胞集团公司9月18日盘中最高价报33.96元。本周关注点公司公告汇总：神州安元等股东拟合计减持不超过4,394,500股，占公司总股本不超过0.94%。上述股东因个人资金需求，计划通过集中竞价方式合计减持不超过4,394,500股，占公司总股本不超过0.94%，减持期间为2026年10月13日至2027年1月12日。公司控股股东、实际控制人承诺不参与本次减持。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000000315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668090967","title":"神州细胞：9月16日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2668090967","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668090967?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:03","pubTimestamp":1789650184,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月17日神州细胞发布公告称公司于2026年9月16日召开业绩说明会。融资融券数据显示该股近3个月融资净流出934.52万，融资余额减少；融券净流入123.0万，融券余额增加。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700034796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667568970","title":"神州细胞(688520.SH)股东拟合计减持不超0.94%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2667568970","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667568970?lang=zh_cn&edition=full","pubTime":"2026-09-13 15:46","pubTimestamp":1789285585,"startTime":"0","endTime":"0","summary":"智通财经APP讯，神州细胞(688520.SH)发布公告，公司于近日收到股东暨员工持股平台神州安元、神州安恒、神州安成、神州安弘送达的《关于股份减持计划的告知函》，神州安元、神州安恒、神州安成、神州安弘因个人资金需求，计划通过集中竞价方式减持其持有的公司股份，合计不超过439.45万股(含本数)，占公司总股本不超过0.94%，减持期间为公告披露之日起15个交易日后的3个月内。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663507122","title":"神州细胞（688520）披露2026年半年度报告，8月31日股价下跌3.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663507122","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663507122?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:03","pubTimestamp":1788170618,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，神州细胞报收于35.07元，较前一交易日下跌3.73%，最新总市值为164.95亿元。该股当日开盘36.23元，最高36.23元，最低34.85元，成交额达1.08亿元，换手率为0.69%。公司于近日披露《2026年半年度报告》。公告显示，截至报告期末，公司总资产为3,961,598,391.90元，较上年度末增长3.59%；归属于上市公司股东的净资产为633,391,841.97元，较上年度末增长393.78%。研发投入占营业收入的比例为58.89%，较上年同期增加18.98个百分点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100025865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663484610","title":"神州细胞（688520）2026年中报简析：净利润同比下降982.86%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2663484610","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663484610?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:17","pubTimestamp":1788041849,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期神州细胞发布2026年中报。截至本报告期末，公司营业总收入6.59亿元，同比下降32.16%，归母净利润-3.66亿元，同比下降982.86%。按单季度数据看，第二季度营业总收入3.36亿元，同比下降25.67%，第二季度归母净利润-1.9亿元，同比下降94.8%。本报告期神州细胞三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达37.06%。本文数据来源于神州细胞2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663180590","title":"图解神州细胞中报：第二季度单季净利润同比下降94.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663180590","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663180590?lang=zh_cn&edition=full","pubTime":"2026-08-29 03:05","pubTimestamp":1787943921,"startTime":"0","endTime":"0","summary":"证券之星消息，神州细胞2026年中报显示，上半年度公司主营收入6.59亿元，同比下降32.16%；归母净利润-3.66亿元，同比下降982.86%；扣非净利润-3.16亿元，同比下降775.87%；其中2026年第二季度，公司单季度主营收入3.36亿元，同比下降25.67%；单季度归母净利润-1.9亿元，同比下降94.8%；单季度扣非净利润-1.69亿元，同比下降182.74%；负债率83.84%，投资收益126.28万元，财务费用3571.32万元，毛利率90.31%。财报数据概要请见下图:本文数据来源于神州细胞2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900006528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661321122","title":"每周股票复盘：神州细胞（688520）SCTA02A获乙肝临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2661321122","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661321122?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:31","pubTimestamp":1787423469,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，神州细胞报收于37.89元，较上周的39.4元下跌3.83%。本周，神州细胞8月20日盘中最高价报43.55元。SCTA02A为重组抗HBsAg单克隆抗体注射液，当前乙肝功能性治愈手段有限，临床需求较高。神州细胞控股子公司神州细胞工程有限公司获国家药品监督管理局批准，其自主研发的SCTB10注射液开展A型血友病I/II期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660044429","title":"神州细胞最新公告：控股子公司产品SCTA02A获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660044429","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660044429?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:22","pubTimestamp":1787134959,"startTime":"0","endTime":"0","summary":"神州细胞(688520.SH)公告称，公司控股子公司神州细胞工程收到国家药监局核准签发的《药物临床试验批准通知书》，同意自主研发产品SCTA02A注射液开展慢性乙型肝炎的临床试验。该产品是公司以功能性治愈慢性乙肝为目标设计的产品组合中首个获批临床的品种，本次获批开展I期临床试验。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900032307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645539860","title":"神州细胞冲刺港股IPO：集采重创“现金奶牛”，盈亏反复造血乏力，烧钱不止负债攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2645539860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645539860?lang=zh_cn&edition=full","pubTime":"2026-06-24 15:11","pubTimestamp":1782285118,"startTime":"0","endTime":"0","summary":"神州细胞2025年经营现金流告负，流动负债缺口进一步扩大。截至2025年12月31日，安佳因已纳入国内20余个省级地区的省际联盟集中采购目录。神州细胞坦言，客户集中度相对较高，失去任何主要客户都可能对业务、经营业绩及财务状况造成不利影响。证券之星注意到，高毛利背后，神州细胞的盈亏反复。神州细胞表示，港股融资旨在打造国际化资本运作平台，拓宽全球资金渠道，增强长期资本实力。截至2025年末，神州细胞","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026062400022240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793774341851,"stockEarnings":[{"period":"1week","weight":-0.0464},{"period":"1month","weight":-0.1841},{"period":"3month","weight":-0.1654},{"period":"6month","weight":-0.2948},{"period":"1year","weight":-0.4429},{"period":"ytd","weight":-0.302}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0609},{"period":"3month","weight":-0.0697},{"period":"6month","weight":-0.1368},{"period":"1year","weight":-0.0926},{"period":"ytd","weight":-0.0909}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京神州细胞生物技术集团股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13406人(较上一季度增加16.93%)","perCapita":"33219股","listingDate":"2020-06-22","address":"北京市大兴区北京经济技术开发区科创七街31号院5号楼307","registeredCapital":"47033万元","survey":" 北京神州细胞生物技术集团股份公司的主营业务是治疗性抗体、重组蛋白及疫苗的研发、生产与商业化。公司的主要产品是重组蛋白药物、抗体药物。","listedPrice":25.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神州细胞(688520)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神州细胞(688520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神州细胞,688520,神州细胞股票,神州细胞股票老虎,神州细胞股票老虎国际,神州细胞行情,神州细胞股票行情,神州细胞股价,神州细胞股市,神州细胞股票价格,神州细胞股票交易,神州细胞股票购买,神州细胞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神州细胞(688520)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神州细胞(688520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}